Firestone Institute for Respiratory Health, Depts of Medicine, McMaster University, Hamilton, ON, Canada. 2 Dept of Pharmacology, Shimane University School of Medicine, Shimane, Japan.
Eur Respir Rev. 2013 Dec;22(130):552-7. doi: 10.1183/09059180.00007713.
Fibrocytes are bone marrow-derived, circulating mesenchymal progenitor cells that play a role in several fibrotic disorders, including lung fibrosis. They are attracted to injured tissue by various chemokines. It is likely that fibrocytes play a detrimental role in tissue homeostasis and promote fibrosis, although this paradigm needs further confirmation. This would make fibrocytes a possible novel treatment target for fibrotic disorders. Fibrocytes also have some potential as a biomarker for idiopathic pulmonary fibrosis (IPF) and other diseases, but the promising preliminary data from single centre studies still require independent validation. Despite several, as yet, unresolved issues, it has become clear that fibrocytes are more than an incidental finding in lung injury and repair, and may hold great promise for the future of IPF management.
成纤维细胞是骨髓来源的循环间充质祖细胞，在多种纤维化疾病中发挥作用，包括肺纤维化。它们通过各种趋化因子被吸引到受损组织。成纤维细胞可能在组织稳态中发挥有害作用并促进纤维化，尽管这一范式需要进一步证实。这将使成纤维细胞成为纤维化疾病的一个潜在的新治疗靶点。成纤维细胞也有可能成为特发性肺纤维化 (IPF) 和其他疾病的生物标志物，但来自单个中心研究的有希望的初步数据仍需要独立验证。尽管存在几个尚未解决的问题，但已经清楚的是，成纤维细胞不仅仅是肺损伤和修复中的偶然发现，并且可能为 IPF 管理的未来带来巨大希望。
